(Circulation. 2000;102:2051.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Novel, Bedside, Tissue Factor–Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy
From the Departments of Medicine and Biochemistry (K.G.M.), University of Vermont College of Medicine, Burlington.
Background—Because optimal use of combinations of antiplatelet and antithrombotic drugs requires improved methods for assessment of therapeutic efficacy, we developed an assay designed to increase sensitivity that is based on initiation of clotting by tissue factor in minimally altered whole blood.
Methods and Results—Blood samples were obtained from healthy subjects, and the contact pathway of coagulation was inhibited with corn trypsin inhibitor (a specific factor XIIa inhibitor without effect on other coagulation factors). Clotting was initiated with relipidated tissue factor and detected with a Hemochron ACT instrument. Results were reproducible with samples from 25 healthy volunteers (mean time to clot, 125±17 seconds). Blood was also exposed to pharmacological concentrations of antithrombotic and antiplatelet agents in vitro. Heparin (0.25 anti-IIa/Xa U/mL) prolonged the time to clot by 2.4-fold (172 seconds, P<0.05); hirudin (1.0 anti-IIa U/mL), by 3-fold (250 seconds P<0.05); and enoxaparin (0.6 anti-Xa U/mL), by 2 -fold (123 seconds, P<0.05). Additive effects of antiplatelet agents were readily detectable with both heparin and hirudin. Thus, addition of 3 µg/mL abciximab to 1.0 anti-IIa/Xa U/mL heparin and to 1.0 anti-IIa U/mL hirudin further prolonged the times to clot by 140 and 67 seconds, respectively (P<0.05 for each). Addition of abciximab to enoxaparin did not further prolong the time to clot (increment, 13 seconds; P=NS).
Conclusions—The assay developed should facilitate improved dose selection, titration, and monitoring of combination antithrombotic and antiplatelet treatment regimens.
Key Words: coagulation • anticoagulants • platelets
This article has been cited by other articles:
 |
|
 |
|
  U. M. Okorie, W. S. Denney, M. S. Chatterjee, K. B. Neeves, and S. L. Diamond Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow Blood, April 1, 2008; 111(7): 3507 - 3513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Goel and Scott. L. Diamond Neutrophil Cathepsin G Promotes Prothrombinase and Fibrin Formation under Flow Conditions by Activating Fibrinogen-adherent Platelets J. Biol. Chem., March 7, 2003; 278(11): 9458 - 9463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Mann, S. Butenas, and K. Brummel The Dynamics of Thrombin Formation Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Goel and S. L. Diamond Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma Blood, November 15, 2002; 100(10): 3797 - 3803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Butenas, K. E. Brummel, R. F. Branda, S. G. Paradis, and K. G. Mann Mechanism of factor VIIa-dependent coagulation in hemophilia blood Blood, February 1, 2002; 99(3): 923 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Goel and S. L. Diamond Neutrophil Enhancement of Fibrin Deposition Under Flow Through Platelet-Dependent and -Independent Mechanisms Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|